Genelux Corporation

Genelux Corporation is a privately-held, clinical-stage biopharmaceutical company that is primarily focused on the development of oncolytic virotherapy and tumor imaging technologies for the treatment of cancer. The company was founded in 2001 and is headquartered in San Diego, California, United States.

History

Genelux Corporation was established in 2001 with the aim of developing innovative, proprietary oncolytic virotherapy and tumor imaging technologies. The company's research and development efforts are primarily focused on the creation of novel oncolytic viruses that can selectively replicate in cancer cells, leading to their destruction, while sparing healthy cells.

Oncolytic Virotherapy

Oncolytic virotherapy is a form of cancer therapy that uses viruses to infect and kill cancer cells. Genelux Corporation's oncolytic virotherapy platform is based on the Vaccinia virus, which has a natural propensity for infecting cancer cells. The company has engineered the virus to enhance its cancer-killing abilities and to express biomarkers that allow for the non-invasive imaging of the virus in the body.

Tumor Imaging

In addition to its oncolytic virotherapy platform, Genelux Corporation has developed a tumor imaging technology that allows for the non-invasive visualization of tumors in the body. This technology is based on the expression of biomarkers by the company's engineered Vaccinia virus, which can be detected using standard imaging techniques.

Clinical Trials

Genelux Corporation has conducted several clinical trials to evaluate the safety and efficacy of its oncolytic virotherapy and tumor imaging technologies. These trials have involved patients with various types of cancer, including melanoma, head and neck cancer, and colorectal cancer.

See Also

• Oncolytic virus
• Cancer therapy
• Clinical trial
• Vaccinia virus

External Links

• Official website

This article is a stub related to pharmacology. You can help WikiMD by expanding it!